Emcure Pharma Q2 Profit Rises 29% on Strong International Business Growth
Emcure Pharmaceuticals reported a 29.3% year-on-year rise in consolidated net profit to Rs 325.06 crore for Q2 FY27, driven by strong international business growth. Revenue increased to Rs 2,820.47 crore, with international markets growing 34% and domestic sales up 11-12%. EBITDA rose 30.9%, improving margins. Key international regions included Europe, Canada, and other global markets. Chairman Satish Mehta expressed optimism about sustaining momentum into the second half of FY27. Shares rose over 5% on the BSE and up to 7.3% on the NSE following the results.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (69/100). Lens Score 36/100.
Outlets measured: businessstandard, news18, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (68–70/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 3 Nov, 10:41 am. Other outlets followed.